Effectiveness of a synthetic human recombinant epidermal growth factor in diabetic patients wound healing : Pilot , double‐blind , randomized clinical controlled trial

2021 ◽  
Author(s):  
Bianca Campos Oliveira ◽  
Beatriz Guitton Renaud Baptista Oliveira ◽  
Gabriela Deutsch ◽  
Fernanda Soares Pessanha ◽  
Selma Rodrigues Castilho
Keyword(s):  
Wound Healing ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Controlled Trial ◽  
Diabetic Patients ◽  
Double Blind ◽  
Epidermal Growth

scholarly journals Cost of treatment and reduction achieved by chronic ulcer in diabetic patients - a comparison between hydrogel and human recombinant Epidermal Growth Factor

2019 ◽  
Author(s):  
Gabriela Deutsch ◽  
Bianca Campos de Oliveira ◽  
Fernanda Soares Pessanha ◽  
Keila Mara Cassiano ◽  
Beatriz Guitton Renaud Baptista de Oliveira ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Wound Care ◽  
Intervention Group ◽  
Cost Benefit ◽  
Control Group ◽  
Diabetic Patients ◽  
Double Blind ◽  
Epidermal Growth ◽  
Reduction Cost

Abstract Background: The study provides results from a double-blind clinical trial of 25 patients with diabetic or venous chronic ulcers. The main focus was to evaluate the assessing cost of outpatient treatment with two technologies: 2% carboxymethylcellulose hydrogel or human recombinant Epidermal Growth Factor carbogel. Methods: Patients were randomly allocated to two ulcer treatment groups, human recombinant Epidermal Growth Factor carbogel treated (intervention group, n = 14), and 2% carboxymethylcellulose hydrogel (CMC) (control group, n = 11); both treated during 90 days. To calculate the costs of each patient's procedures, direct costs and human resources costs were measured in Brazilian currency and converted into US dollars. Statistical analysis of clinical data was performed based on intention to treat. For each treatment were analyzed the proportion of cases with wound reduction; cost benefit of the treatment given by the average value of each 1cm2 wound reduction; statistics on the cost of reducing each cm2 of wound for each patient presenting wound reduction. Results: In all evaluated periods, the proportion of cases with decreased lesion area was higher in the intervention group; It presented better cost-benefit ratio and lower average and median reduction cost for each reduced cm2 of the wound. Conclusion: Data suggested that growth factor therapy may be cost-effective and innovative complement to standard wound care.

Sign in / Sign up

Export Citation Format

Share Document